Last edition
News about "Jinzi Jason Wu"
Ascletis Submits 2 IND Applications to the US FDA for the Treatment of Obesity
Ascletis has submitted two IND applications to the US FDA for once-monthly obesity therapies, including ASC36_35, a first-in-class triple-target candidate acting on amylin receptor, GLP-1R and GIPR.
Jinzi Jason Wu | 06/07/2026 | By Akanki
Ascletis Receives FDA IND Clearance for Phase II ASC30 Diabetes Study
Ascletis has received US FDA IND clearance to initiate a 13-week phase-II, randomised, double-blind, placebo-controlled, multi-centre study evaluating the efficacy, safety and tolerability of its oral small-molecule GLP-1 candidate ASC30 in participants with diabetes, with enrollment expected to begin in the first quarter of 2026.
Jinzi Jason Wu | 05/01/2026 | By News Bureau | 164
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy